Brooklyn, NYFounded 2016176+ employeesPrivate
$330M raisedGrowth· last: series d (Nov 2025)· 6 rounds
Backed by(32 investors)
Double Point Ventures · LeadARCH Venture Partners · LeadKhosla Ventures · LeadMax Hodak · LeadNeurotechnology Investors · LeadSigma Partners · Lead+8 more
Synchron is developing a minimally invasive brain-computer interface called Stentrode. Implanted via the blood vessels (no open brain surgery), it enables patients with severe paralysis to control digital devices, with FDA breakthrough device designation.
